European Atomic Energy Community Euratom

The European Atomic Energy Community (Euratom) is an international organization established by the Euratom Treaty of 1957, which became effective on January 1, 1958. Though de jure a distinct entity, it operates de facto under the authority of the European Union, sharing its membership and many institutions, including the European Commission as its administrative body. Euratom is not a commercial company and thus does not report traditional financial metrics or employee counts.

Euratom's core mission is to promote and coordinate the peaceful use of nuclear energy in Europe. Its activities include creating a specialist market for nuclear power, developing nuclear energy, and distributing it among member states. Key operations involve coordinating member states' research programs in nuclear fission and radiation protection, establishing uniform safety and health standards against ionizing radiation, ensuring a secure supply of atomic energy through monitoring, and managing radioactive waste. Euratom is also a global leader in fusion research, significantly participating in projects like the International Thermonuclear Experimental Reactor (ITER).

In patent litigation, Euratom exhibits the posture of an operating entity defending against patent challenges. The available data indicates one tracked case where it appeared as a defendant and zero cases as a plaintiff. This strongly suggests it is not a Non-Practicing Entity (NPE) but rather an active organization involved in the development and regulation of nuclear technologies.

The single tracked case involving Euratom is Fusion Pharmaceuticals, Inc. v. European Atomic Energy Community Euratom et al., filed on February 13, 2023, before the Patent Trial and Appeal Board (PTAB). This proceeding typically involves challenges to the validity of existing patents, consistent with an entity defending its intellectual property or the patents related to its operational scope.